Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enzon misses Street EPS

ENZN reported an adjusted net loss of $113,000 for the first quarter of fiscal 2005. This

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE